- Home
- IIIV vs ARVN Comparison
IIIV vs ARVN Comparison
Compare IIIV & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- ARVN
- Stock Information
- Founded
- IIIV 2012
- ARVN 2015
- Country
- IIIV United States
- ARVN United States
- Employees
- IIIV N/A
- ARVN N/A
- Industry
- IIIV EDP Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- ARVN Health Care
- Exchange
- IIIV Nasdaq
- ARVN Nasdaq
- Market Cap
- IIIV 720.4M
- ARVN 676.2M
- IPO Year
- IIIV 2018
- ARVN 2018
- Fundamental
- Price
- IIIV $29.24
- ARVN $11.27
- Analyst Decision
- IIIV Buy
- ARVN Buy
- Analyst Count
- IIIV 6
- ARVN 23
- Target Price
- IIIV $34.33
- ARVN $17.80
- AVG Volume (30 Days)
- IIIV 155.6K
- ARVN 2.4M
- Earning Date
- IIIV 11-17-2025
- ARVN 11-05-2025
- Dividend Yield
- IIIV N/A
- ARVN N/A
- EPS Growth
- IIIV N/A
- ARVN N/A
- EPS
- IIIV 5.56
- ARVN N/A
- Revenue
- IIIV $248,271,000.00
- ARVN $312,300,000.00
- Revenue This Year
- IIIV N/A
- ARVN N/A
- Revenue Next Year
- IIIV $3.86
- ARVN N/A
- P/E Ratio
- IIIV $5.28
- ARVN N/A
- Revenue Growth
- IIIV 25.08
- ARVN 93.86
- 52 Week Low
- IIIV $22.20
- ARVN $5.90
- 52 Week High
- IIIV $33.97
- ARVN $28.70
- Technical
- Relative Strength Index (RSI)
- IIIV 34.23
- ARVN 73.05
- Support Level
- IIIV $29.19
- ARVN $9.27
- Resistance Level
- IIIV $30.09
- ARVN $10.18
- Average True Range (ATR)
- IIIV 1.03
- ARVN 0.45
- MACD
- IIIV -0.30
- ARVN 0.12
- Stochastic Oscillator
- IIIV 9.42
- ARVN 91.60
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.